AMPK: an emerging drug target for diabetes and the metabolic syndrome.

By Bei B. Zhang, Gaochao Zhou, Cai Li. Cell Metabolism, 2009

1,075 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan (2011, background): “There are extensive reviews concerning the role of AMPK in type II diabetes and metabolic syndrome [86, 87], cardiovascular diseases [88, 89], and cancer [90].”
Metabolic flexibility in health and disease (2017, neutral): “AMPK activators (AICAR, Methotrexate, and Metformin) have also shown promising results in targeting metabolic flexibility to treat metabolic disease (Hardie, 2013; Zhang et al., 2009).”
Mechanisms of insulin resistance in obesity (2013, background): “Activation of AMPK represents a promising approach for improvement of insulin sensitivity [92].”
Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease (2010, neutral): “Similar arguments, although speculative, could be made for metformin, rapamycin, or AMP-K activators, which modulate nutrient-sensing and related pathways (Tsang et al., 2007; Zhang et al., 2009a).”